Cevimeline

220px
220px
Cevimeline
Systematic (IUPAC) name
2-methyspiro(1,3-oxathiolane-5,3)quinuclidine
Identifiers
CAS number	107233-08-9
ATC code	?
PubChem	83898
DrugBank	APRD00224
Chemical data
Formula	C10H17NOS
Mol. mass	489.565 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	< 20%
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Cevimeline is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome.

Mechanism of action

By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.

Side effects

Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.

See also

• Sjögren's syndrome

External links

• Evoxac - Manufacturer's home pageit:cevimelina